KPV // Anti-Inflammatory Tripeptide
A three-amino acid fragment of alpha-MSH that suppresses NF-κB — the master inflammatory switch — without any of the melanocortin side effects like tanning or appetite changes. Specifically effective for gut inflammation, IBD, and IBS. The most targeted anti-inflammatory peptide available for the GI tract.
The inflammation off-switch.
KPV is the minimum effective fragment of alpha-MSH — three amino acids that retain the anti-inflammatory signaling while eliminating the melanocortin receptor side effects. It targets NF-κB, the master transcription factor behind virtually all chronic inflammatory responses.
Oral for gut, SubQ for systemic.
KPV's oral route is preferred for GI conditions — direct mucosal contact maximizes gut anti-inflammatory effects. SubQ provides systemic anti-inflammatory coverage for non-GI applications.
Alpha-MSH anti-inflammatory research.
The anti-inflammatory properties of alpha-MSH peptides are well established in immunology literature. The parent molecule, alpha-MSH, is a potent endogenous anti-inflammatory agent — but its melanocortin receptor activity limits clinical application.
KPV represents the minimum effective fragment — retaining the NF-κB suppressive activity without melanocortin side effects. Research in animal models of colitis has demonstrated significant reductions in inflammatory markers and tissue damage with KPV treatment.
The oral bioavailability of KPV for GI applications is particularly promising. As a tripeptide, it has direct contact with intestinal epithelium before systemic absorption, making it uniquely positioned for inflammatory bowel conditions where topical mucosal delivery matters most.
Anti-inflammatory peptide landscape.
| Compound | Target | Route | GI Specific | Side Effects |
|---|---|---|---|---|
| KPV | NF-κB | Oral / SubQ | ✓ Primary target | Minimal |
| BPC-157 | Growth Factors | SubQ / Oral | ✓ GI healing | Minimal |
| VIP | CIRS/Pulmonary | Nasal | Indirect | Possible hypotension |
| Larazotide | Zonulin/Tight Junction | Oral | ✓ Barrier repair | Minimal |
What to watch for.
KPV's side effect profile is manageable with proper protocol adherence. Baseline blood work before starting and periodic monitoring during use is essential.
- Very well tolerated in reported use
- Mild GI effects during initiation (rare)
- No tanning (unlike full alpha-MSH)
- No appetite changes (unlike MC4R agonists)
- No sexual side effects
- Limited human safety data — research compound
- CRP / high-sensitivity CRP
- ESR (erythrocyte sedimentation rate)
- Fecal calprotectin (GI inflammation marker)
- Complete blood count with differential
- Comprehensive metabolic panel
- Cytokine panel (if available — TNF-α, IL-6)
- BPC-157 Oral for combined GI healing + anti-inflammation
- Larazotide for GI barrier repair (tight junctions)
- Thymosin Alpha-1 for immune balance during gut protocols
- Oral route preferred for IBD/IBS — direct mucosal contact
- Can be combined with conventional IBD medications
- No known peptide interactions
- Lyophilized: refrigerate at 2–8°C (36–46°F)
- Reconstituted: refrigerate, use within 21 days
- Oral formulations: follow manufacturer storage guidelines
- Protect from light and heat
- Tripeptide — relatively stable
Compounds that complement KPV.
The cleanest anti-inflammatory in the peptide toolbox.
KPV does one thing exceptionally well — suppress NF-κB-driven inflammation without off-target effects. For IBD, IBS, and gut-specific inflammation, the oral route gives you direct mucosal delivery that systemic anti-inflammatories can't match. Stack it with BPC-157 Oral for healing and Larazotide for barrier repair to build the most comprehensive gut protocol available. Limited human data means this is still research-grade territory — but the mechanism is clean, the safety profile appears excellent, and the GI-targeted application makes it unique. Track fecal calprotectin and hsCRP before and during.
Our free Protocol Guide includes the complete Gut Repair Stack — KPV, BPC-157 Oral, and Larazotide timing, inflammatory markers, and tracking templates.